The incidence of (para) thyroid disorders ten years after the introduction of a new thyroid protection during 131I-MIBG treatment in children with neuroblastoma

Completed

• Conditions: Hypothyroidism; thyroid dysfunction; thyroid nodules; 10043739

• Registration Number: NL-OMON37078
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 50

Inclusion Criteria

All neuroblastoma patients treated with 131I-MIBG, in the period 1999 until 2011 (who received the DBR profylaxe for thyroid protection) in Emma Children*s Hospital and Sophia Children*s Hospital will be evaluated and included in the study

Exclusion Criteria

All neuroblastoma patients who were not treated with 131I-MIBG .

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Thyroid dysfunction (TSH and FT4) and the occurrence of thyroid<br /><br>nodules/carcinoma. Thyroid dysfunction is defined as having TSH > 4.5 mU/L or<br /><br>using T4 at the last moment of follow-up. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Incidence of hyperparathyroidism and the occurrence of adenomas in the<br /><br>parathyroid glands. </p><br>